Alphabet's self-driving unit Waymo has raised $16 billion in a landmark funding round, valuing the company at $126 billion. The capital injection, backed by major investors including Alphabet and Dragoneer, is set to fuel an aggressive international expansion of its autonomous ride-hailing service.
As FormFactor prepares to release its Q4 results, the semiconductor equipment sector shows robust momentum. Investors are watching to see if the company can maintain its track record of exceeding expectations amid a mixed industry landscape.
All eyes are on healthcare giant McKesson as it prepares to report fourth-quarter results. With a history of revenue misses and a slowing growth rate, analysts and investors are keen to see if the company can deliver a positive surprise.
As ePlus prepares to release its fourth-quarter results, investors are weighing strong past performance against a history of revenue misses and a cautious growth outlook for the current period.
Medical device giant Boston Scientific (BSX) is scheduled to release its fourth-quarter financial results before market open on Wednesday, with Wall Street anticipating continued strong revenue growth and another potential earnings beat.
CDW Corporation is set to report its fourth-quarter earnings before the market opens on Wednesday. Analysts project modest revenue growth, but the company's recent performance and broader sector trends suggest a cautious outlook.
Across India's villages and small towns, a new generation of workers is logging on after sunset to label the data that trains the world's most advanced AI systems. This quiet workforce, many of them women and first-generation graduates, is finding economic opportunity while reshaping global tech's supply chain.
Despite stellar fundamentals and a dominant market position, Mastercard's premium valuation is prompting a debate among investors. While bulls champion its profitability and growth, skeptics warn of overextension, suggesting a pullback may offer a more attractive entry point.
Nurix Therapeutics, a clinical-stage biopharma company, is gaining attention for its novel protein degradation platform. With strong early data for its lead drug, key regulatory designations, and strategic partnerships with industry giants, the company is positioning itself to address unmet needs in multi-billion dollar oncology markets.
Beyond the headlines of cash burn and production woes, Rivian Automotive is executing a strategic pivot. With falling costs, the imminent launch of its mass-market R2, and a growing software revenue stream, the company is laying the groundwork to transform from a pure EV manufacturer into a vertically integrated autonomy platform.
Twist Bioscience's proprietary silicon-based DNA manufacturing platform is driving double-digit revenue growth and margin expansion, positioning the synthetic biology tools provider on a clear path to adjusted EBITDA breakeven by fiscal 2026.
ASGN Inc. is set to report its fourth-quarter financial results after the bell on Wednesday, with Wall Street anticipating another year-over-year revenue decline. Investors will scrutinize the performance for signs of stabilization in a competitive sector.
A sophisticated, high-conviction options trade by a large investor signals strong confidence in Edwards Lifesciences' fundamentals, with a potential breakout eyed for early 2026 tied to regulatory milestones and sustained growth in its mitral valve business.
French biotech Abivax sees renewed investor interest following strong Phase 3 data for its oral therapy obefazimod in hard-to-treat ulcerative colitis, with analysts pointing to a clear path to regulatory approval and significant market potential.
Despite facing near-term pressures from a softer ad market and intensified competition, The Trade Desk's leadership in programmatic advertising and its scalable platform present a compelling case for patient investors eyeing the sector's structural shift.
Shares of IT staffing and services provider ASGN Incorporated are trading at what some analysts call deeply discounted multiples, sparking a debate on whether the market is overlooking its resilient cash flow and diversified operations.
Amidst market volatility, EVERTEC Inc. (EVTC) presents a compelling investment case. Trading at depressed valuation multiples, the Latin American transaction processing leader combines a 'boring but consistent' operational profile with significant potential for multiple expansion and steady growth, offering a unique risk/reward balance for patient investors.
While flashy jets and missiles capture public attention, L3Harris Technologies operates in the critical, unseen layers of connectivity and electronic warfare. As global tensions and technological threats evolve, its role as a foundational enabler of next-generation defense systems is driving a compelling investment thesis centered on resilience and information dominance.
Amid rising global tensions and sustained U.S. defense spending, Lockheed Martin's unique role in stitching together America's missile and space defense architecture presents a compelling investment case, analysts argue.
As the U.S. Department of Defense advances its layered 'Golden Dome' missile defense concept, aerospace and defense giant RTX Corporation emerges with a commanding portfolio of existing, scalable systems—from Patriot interceptors to advanced radars—positioning it for sustained growth amid heightened global security demands.
